Biologic Treatments for Moderate to Severe Atopic Dermatitis

July 7th 2022

Sleep disturbance is a significant factor in reduced quality of life for children and adolescents. A study at a poster session for the SPD 2022 47th Annual Meeting was presented on treating this population with dupilumab (Dupixent) to help with sleep quality showed positive results.

January 31st 2020

The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.

December 16th 2019

LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.

December 11th 2019

The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.